Training Accredited Social Health Activists (ASHA) to Identify Babies with Spinal Muscular Atrophy: Experts Urge Early Action to Combat Rare Disease in India

Spread the Message

Read Time:4 Minute, 50 Second

In a landmark move to strengthen rare disease detection, health experts across India are advocating for the systematic training of Accredited Social Health Activists (ASHA) to identify early signs of Spinal Muscular Atrophy (SMA) in infants. On August 30, 2025, at a New Delhi health summit, specialists emphasized the urgent need for grassroots awareness and screening for this devastating neuromuscular disorder, as India struggles with delayed diagnoses and limited treatment access.

What is Spinal Muscular Atrophy?

Spinal Muscular Atrophy (SMA) is a rare, genetic disorder affecting motor neurons—the cells responsible for voluntary muscle movement. While intellectual abilities remain unaffected, children with SMA experience profound loss of muscle function, resulting in progressive weakness and disability. The disorder stems from mutations in the SMN1 gene, leading to reduced levels of the survival motor neuron protein.

SMA is categorized into types 0 through 4:

Type 0: Fatal at birth due to a complete lack of muscle function.
Type 1: Infants fail to attain basic milestones like neck control, often resulting in death within the first year without intervention.
Types 2–4: Characterized by varying degrees of motor impairment, with Type 2 and 3 symptoms emerging in early childhood and adolescence.

India’s Current Landscape: Prevalence and Gaps

Recent government data report 295 cases in the national registry, with nearly half of affected children diagnosed before age one. Studies estimate the incidence of SMA at roughly 1 in 7,500 to 1 in 10,000 live births in India, though carrier frequency may be as high as 1 in 30 among North Indians. This suggests substantial underdiagnosis and highlights the need for population-wide carrier screening.

Despite the burden, India faces critical challenges:

Delayed Diagnosis: Many parents misinterpret symptoms as mere developmental delays, missing early intervention windows.
Limited Access to Genetic Testing: Comprehensive facilities for confirmatory tests remain scarce outside urban centers.
Lack of National Registry: Incomplete data impairs public health planning, funding allocation, and equitable treatment.
Funding Barriers: Innovative therapies are available but are prohibitively expensive for most families.

The Imperative for ASHA Training

Experts, including Dr. Rahul UR (State Nodal Officer, National Health Mission, Kerala), stress the pivotal role of ASHA workers in rural health delivery. ASHA workers—India’s primary community health bridge—are uniquely positioned to observe infants and counsel parents on developmental milestones.

Training ASHAs to spot warning signs such as:

Lack of neck control by appropriate age
Failure to sit, stand, or walk within expected developmental windows
can enable timely referrals and, potentially, life-saving interventions.

Expert Perspective

Professor Sheffali Gulati, pediatric neurologist at AIIMS, New Delhi, comments: “The SMA ecosystem in India faces critical gaps—delayed diagnosis, limited genetic testing access, and lack of sustainable funding. Community awareness and early screening must be prioritized to improve outcomes for children with this debilitating condition”.

Recent Advances in Treatment

In the last decade, SMA treatment has transformed dramatically. Disease-modifying therapies—including risdiplam (Evrysdi), nusinersen (Spinraza), and gene therapy—show unprecedented improvements in motor function and survival among affected children. An Indian study between 2020 and 2023 followed 47 children on various treatments: gene therapy provided a median 4-point motor function increase, compared to 3.5 for nusinersen and 2.5 for risdiplam.

The government has taken steps to ease access, such as waiving customs duty on SMA drugs imported for personal use and launching a Production Linked Incentive Scheme for domestic orphan drug manufacturing.

Why Early Diagnosis Matters

Research underscores the benefits of intervention before symptom onset, with earlier treatment correlating to dramatically better outcomes. Delays—often caused by lack of awareness—can result in rapid muscle degeneration and, in severe cases, early mortality especially in infants.

Practical Implications for Families and Providers

For parents:

Maintain a developmental calendar and seek medical advice if milestones (e.g., head control by 3 months, sitting by 6 months) are not met.
Request referral for genetic testing if red flags are observed.

For healthcare workers:

Integrate basic SMA screening into child health checkups, especially in high-risk populations.
Advocate for broader state and district-level newborn screening programs.

Public Health Implications

Training ASHA workers in SMA identification:

Promotes early detection, enabling quicker access to treatment.
Fosters community engagement, reducing stigma and misconceptions about developmental disorders.
Contributes to robust data collection, aiding public health planning and research.

Government initiatives like the National Policy for Rare Diseases (2021) set a foundation, but experts stress that success will require coordinated action among government agencies, healthcare providers, NGOs, and patient bodies.

Limitations and Counterpoints

While innovative treatments exist, access remains uneven, and long-term safety data—especially for gene therapies—are still evolving. The absence of standardized diagnostic protocols and a unified national registry hinders comprehensive disease management. Additionally, rural communities may face entrenched barriers due to limited resources and patchy healthcare infrastructure.

Expert Quotes

Dr. Rahul UR, Kerala NHM: “Missing key milestones, such as attaining neck control or standing, are critical indicators. Training ASHA workers is a major boost in the fight against SMA”.
Prof. Sheffali Gulati, AIIMS: “India urgently needs sustainable funding and systematic awareness to ensure timely diagnosis and access to life-changing therapies”.

Balanced Perspective

As SMA treatments become more effective and available, integrating community-based screening and education—especially via ASHA workers—could narrow diagnosis and treatment gaps. However, success depends on cross-sector collaboration, expanded funding, and persistent efforts to overcome social and infrastructural hurdles.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.